Healthcare
technology companies Zenosense Inc. and International Stem Cell Corp. are
laying significant groundwork with their proactive research in the areas of
MRSA detection and the creation of pluripotent human stem cells from
unfertilized oocytes (eggs). Zenosense is a detection device development
company based in Valencia, Spain. Its mission is to develop, market and sell an
effective MRSA detector, by way of licensed-in technology, for sale to
healthcare providers for use in clinical settings. International Stem Cell
Corporation is focused on the therapeutic applications of human parthenogenetic
stem cells (hpSCs) and the development and commercialization of cell-based
research and cosmetic products.
ZENO recently
announced that they have extended their agreement with the Sgenia Group
(“Sgenia”) to include cancer sensory devices. Under the terms of the extension,
Zenosense has the optional right to fund the development of prospective cancer
sensory devices that may be based on the Sgenia technology. Subject to
providing funding, the company will have the right to manufacture, market and
sell the resulting devices should they be developed.
The company believes
the sensory technology and algorithmic processing in development for MRSA
detection could, if successful, be applied to certain cancer sensory devices.
Some cancers, such as lung and colon, produce volatile organic compounds
(“VOCs”) in an individual’s breath in a similar way to patients infected with
MRSA. Should the cancer specific pattern of VOCs be identified, ZENO believes
that a relatively straightforward modification of a successful MRSA detection
technology may enable it to produce a similar device for the detection of
certain cancers.
Meanwhile,
California based International Stem Cell Corporation, a biotechnology company
developing novel stem cell based therapies and biomedical products, announced
that it will host a conference call on Wednesday, May 14, 2014 to provide a
business update and discuss its financial results for the three months ended
March 31, 2014.
Dr. Simon Craw,
Executive Vice President and Mr. Jay Novak, Chief Financial Officer of
International Stem Cell will host the conference call. To attend the call,
please use the dial-in information below:
Date: Wednesday, May
14, 2014
Time: 11:00 a.m. EST
Conference Number
(U.S.): 1-877-941-2069
International
Dial-In: 1-480-629-9713
Conference ID:
4682485
Webcast:
http://public.viavid.com/confirmation/confirmwebcast.php?id=o5aroJyX
A playback of the
call will be available from 05/14/14 at 5:00 pm ET until 05/28/14 at 11:59 pm
ET. To listen, call 1-877-870-5176 within the United States or 1-858-384-5517
when calling internationally. Please use the replay pin number 4682485.
For more information
on these companies, visit www.zenosense.net and www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
No comments:
Post a Comment